Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma.
Harstrick A, Schmoll HJ, Bokemeyer C, Metzner B, Illiger HJ, Berdel W, Ostermann H, Manegold C, Räth U, Siegert W, et al. Harstrick A, et al. Among authors: ostermann h. J Cancer Res Clin Oncol. 1991;117 Suppl 4:S198-202. doi: 10.1007/BF01613227. J Cancer Res Clin Oncol. 1991. PMID: 1665492 Clinical Trial.
The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C, Harstrick A, Beyer J, Metzner B, Rüther U, Hartmann JT, Holstein K, Derigs HG, de Wit R, Casper J, Schöffski P, Kührer I, Illiger HJ, Kempf B, Reichle A, Föller A, Hossfeld DK, Fischer JT, Berdel WE, Gerhartz HH, Kirchner H, Pflüger KH, Ostermann H, Kanz L, Schmoll HJ. Bokemeyer C, et al. Among authors: ostermann h. Semin Oncol. 1998 Apr;25(2 Suppl 4):24-32; discussion 45-8. Semin Oncol. 1998. PMID: 9578059 Review.
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.
Kropff MH, Lang N, Bisping G, Dominé N, Innig G, Hentrich M, Mitterer M, Südhoff T, Fenk R, Straka C, Heinecke A, Koch OM, Ostermann H, Berdel WE, Kienast J. Kropff MH, et al. Among authors: ostermann h. Br J Haematol. 2003 Aug;122(4):607-16. doi: 10.1046/j.1365-2141.2003.04473.x. Br J Haematol. 2003. PMID: 12899716 Free article. Clinical Trial.
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.
Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A. Borchmann P, et al. Among authors: ostermann h. Lancet Oncol. 2017 Apr;18(4):454-463. doi: 10.1016/S1470-2045(17)30103-1. Epub 2017 Feb 22. Lancet Oncol. 2017. PMID: 28236583 Clinical Trial.
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis.
Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, Peest D, Kaufmann M, Bunjes D, Straka C, Fischer T, Sezer O, Hentrich M, Ostermann H, Bassermann F, Hess G, Hertenstein B, Freund M, Kropff M, Schmidt CA, Wolf HH, Jung W, Frickhofen N, Mielke S, Bargou RC, Maschmeyer G, Svaldi M, Langer CH, Gramatzki M, Hebart H, Kanz L, Einsele H; Deutsche Studiengruppe Multiples Myelom. Knop S, et al. Among authors: ostermann h. Leukemia. 2019 Nov;33(11):2710-2719. doi: 10.1038/s41375-019-0537-2. Epub 2019 Aug 28. Leukemia. 2019. PMID: 31462732 Clinical Trial.
Incidence and severity of ifosfamide-induced encephalopathy.
Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X. Rieger C, et al. Among authors: ostermann h. Anticancer Drugs. 2004 Apr;15(4):347-50. doi: 10.1097/00001813-200404000-00006. Anticancer Drugs. 2004. PMID: 15057138
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
Kreissl S, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P; German Hodgkin Study Group. Kreissl S, et al. Among authors: ostermann h. Lancet Haematol. 2021 Jun;8(6):e398-e409. doi: 10.1016/S2352-3026(21)00101-0. Lancet Haematol. 2021. PMID: 34048679 Clinical Trial.
195 results